The main aim of the ProQuorum probiotic is to provide a safer and more convenient alternative to the existing antibiotic therapies for the C. difficile infection. As such, eliminating the possible side-effects of our system has been at the forefront of our endeavours.
In contrast, typically prescribed antibiotics for clostridial infections such as metronidazole, vancomycin and fidaxomicin, can cause common gastro-intestinal adverse effects, but may, in rare cases, lead to more severe effects such as liver and/or renal insufficiency, as well as low leukocyte counts. To this is added the risk of antimicrobial resistance evolution, which is observed frequently in the case of nosocomial infections such as C. difficile. At the same time, antibiotic treatment further destabilizes the commensal and symbiotic gut flora, which appears to be a contributing factor to the induction of virulence in otherwise asymptomatic C. difficile colonization in the first place.
Thus, in order to avoid all issues associated with antibiotic administration, we are proposing a more specific targeting strategy by delivering the CD27L endolysin to the large intestine with the aid of the Lactobacillus reuteri chassis, which has been shown to safely colonise the gut milieu.